leadf
logo-loader
viewMetal Tiger PLC

Metal Tiger upbeat over prospects for copper

The outlook remains bright given limitations on supply

copper
Outlook is good says Metal Tiger

Mining junior Metal Tiger PLC (LON:MTR) reported a mixed half year with good progress at its Botswana joint venture offset by a drop in the value of its investment portfolio.

Net assets at end June were US$11.5mln or 0.97p per share compared to 1.328p in December.

READ: Metal Tiger gets the go-ahead to drill at the T20 Dome Complex in Botswana

A US$3.1mln fall in the value of its direct investment portfolio was responsible for the dip and accounted for the majority of an interim loss of US$4.5mln.

During the period, Metal Tiger restructured its interest in the T3 joint venture in Botswana and acquired an 18% stake in KML, which is also exploring for copper in the country.

The outlook for copper remains bright, it said, given limitations on supply and the important role of copper in the global economy. 

T3, a joint venture with Australian explorer MOD has the potential to become a world class copper asset, it added.

At the end of August, Metal Tiger raised £6.2m at a price of 2.8p per share. 

Quick facts: Metal Tiger PLC

Price: 27 GBX

AIM:MTR
Market: AIM
Market Cap: £41.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Metal Tiger PLC named herein, including the promotion by the Company of Metal Tiger PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Morning report: FTSE falls as traders get back to their desks

The FTSE is lower after a long weekend despite UK factory output rising by the fastest pace in more than six years, albeit from a low level as businesses begin to get back to work.  Movers and shakers include AstraZeneca (LON:AZN) which has received EU approval for Imfinzi which is to...

2 weeks, 4 days ago

2 min read